Aim: Advanced glycation end products (AGE) predict the development of atherosclerosis. AGE-albumin from poorly controlled diabetes mellitus (DM) patients impairs macrophage cholesterol efflux by reducing ABCA-1. We analyzed if an adequate glycemic control (aGC) is able to prevent alterations in cholesterol efflux elicited by DM-albumin.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2018 Published by Elsevier Inc.